FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
05/07/2026
Back to search
Official data from USPTO
QIAGEN PARTNER
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
QIAGEN PARTNER
ST13
US500000079409549Class
5, 10, 44
Filing
79409549
Registration
7979833
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
05/08/2026
Trademark type
Word
Nice classes
5, 10, 44
Filing date
10/21/2024
Registration date
10/14/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/14/2025
Last transaction
05/08/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
DE
Examiner
CASTRO, GIANCARLO
Law office
M10
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Qiagen GmbH
Representatives
G MATHEW LOMBARD LOMBARD & GELIEBTER LLP
Technical classification
Nice Classes
Class 5Class 10Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Diagnostic preparations for medical or veterinary purposes; diagnostic preparations for humans for medical purposes; preparations for medical and veterinary purposesin particular diagnosticsfor markingamplifyingquantification and/or for the analysis of biopolymersin particular nucleic acids; chemicalbiochemical and biotechnological preparations for medical and veterinary purposesin particular reagentsenzymes and buffer solutions for markingamplifyingquantification and/or for the analysis of biopolymersin particular nucleic acidsin particular reagentsenzymes and buffer solutions for nucleic acid amplification; kits containing preparations for medical and veterinary diagnostic purposesin particular for markingamplifyingquantification and/or for the analysis of biopolymersin particular nucleic acidsin particular reagentsenzymes and buffer solutions for nucleic acid amplification; chemical reagents for medical purposes; cartridges containing medical diagnostic reagents for use in Polymerase Chain Reaction (PCR) or digital Polymerase Chain Reaction (PCR) instruments; medical diagnostic assays for testing of body samplesincluding bodily fluids and tissue in the detectionmonitoringprediction of disease or other conditionsdisease stateshormone leveldrug leveldrug responseorgan function effectivenessclinical response; diagnostic test kits comprised of medical diagnostic reagents and assays for testing in the field of medical diagnostics.
Class 10
Apparatus for medical and veterinary diagnostic analysis and determination of medical and veterinary conditionsnamely DNA and RNA testing apparatus; Medical and veterinary equipment for diagnostic purposes; clinical medical laboratory apparatus and analytical instrumentsnamely digital Polymerase Chain Reaction (d PCR) instruments for use in in-vitro and in-vivo diagnostics; medical devices for detection of infectious diseasedigital polymerase chain reaction (dPCR) platforms; medical devices for use in pre-natal screeningsdigital polymerase chain reaction (dPCR) platform; medical devicesdigital polymerase chain reaction (dPCR) instruments for use in detectingdiagnosing and treating cancer and infectious diseasedigital polymerase chain reaction (dPCR) platform; medical devicesdigital polymerase chain reaction (dPCR) instruments for use in pre-natal screeningsdigital polymerase chain reaction (PCR) platform; medical devicesinstruments for use in measuring and quantifying copy number of DNA for medical diagnostic purposesdigital polymerase chain reaction (dPCR) platform; microfluidic plates for use as medical apparatus.
Class 44
Testing servicesquantifying DNA and RNA for medicaldiagnostic and treatment purposes; rental of digital Polymerase Chain Reaction (PCR) apparatus; RNA or DNA analysis for cancer diagnosis and prognosis; Medical servicesin particular medical analysis in connection with the treatment of individuals; providing information in the fields of medicineveterinary medicine and pharmaceuticals; health centersgenetic centers providing medical diagnosticpreventive and curative therapy services for genetic disorderscancer treatment centersrare disease treatment centerschildren's hospitals and women's hospital; medical clinics; gene therapy services in the field of oncologyinfertilityprenatal diagnosticscarrier testinggenetically inherited diseases; medical laboratory services for the analysis of samples taken from patients.
Publications
History of USPTO decisions and trademark events.
25 publications found
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
04/30/2026
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/23/2026
FIMP
FINAL DISPOSITION PROCESSED
04/23/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/13/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
04/13/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/14/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/14/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
10/14/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/26/2025
PUBO
PUBLISHED FOR OPPOSITION
08/26/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/20/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/23/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/16/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/16/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/16/2025
RFNT
REFUSAL PROCESSED BY IB
03/29/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/11/2025
RFRR
REFUSAL PROCESSED BY MPU
03/11/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/23/2025
CNRT
NON-FINAL ACTION WRITTEN
01/22/2025
DOCK
ASSIGNED TO EXAMINER
01/13/2025
MAFR
APPLICATION FILING RECEIPT MAILED
11/17/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/17/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/14/2024
Continuous trademark protection
Get notified about every new filing that threatens QIAGEN PARTNER or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.